Modus Therapeutics (Sweden) Insiders
| MODTX Stock | 0.31 0.01 3.33% |
Modus Therapeutics employs about 2 people. The company is managed by 2 executives with a total tenure of roughly 5 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Breaking down Modus Therapeutics' management performance can provide insight into the firm performance.
| Claes Lindblad Insider Chief Officer |
| John MD Insider Chief Officer |
Modus |
Modus Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.5419) % which means that it has lost $0.5419 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.2217) %, meaning that it generated substantial loss on money invested by shareholders. Modus Therapeutics' management efficiency ratios could be used to measure how well Modus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Modus Therapeutics maintains a total of 16.1 Million outstanding shares. Modus Therapeutics Holding secures majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 79.18 % of Modus Therapeutics Holding outstanding shares that are owned by insiders conveys that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Modus Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Modus Therapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Modus Therapeutics Workforce Comparison
Modus Therapeutics Holding is rated below average in number of employees category among its peers. The total workforce of Biotechnology industry is now estimated at about 184. Modus Therapeutics claims roughly 2.0 in number of employees contributing just under 2% to stocks in Biotechnology industry.
Modus Therapeutics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Modus Therapeutics Price Series Summation is a cross summation of Modus Therapeutics price series and its benchmark/peer.
Modus Therapeutics Notable Stakeholders
A Modus Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Modus Therapeutics often face trade-offs trying to please all of them. Modus Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Modus Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Claes Lindblad | Chief Officer | Profile | |
| John MD | Chief Officer | Profile |
About Modus Therapeutics Management Performance
The success or failure of an entity such as Modus Therapeutics often depends on how effective the management is. Modus Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Modus management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Modus management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please note, the imprecision that can be found in Modus Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Modus Therapeutics Holding. Check Modus Therapeutics' Beneish M Score to see the likelihood of Modus Therapeutics' management manipulating its earnings.
Modus Therapeutics Workforce Analysis
Traditionally, organizations such as Modus Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Modus Therapeutics within its industry.Modus Therapeutics Manpower Efficiency
Return on Modus Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 10.3M | |
| Net Loss Per Executive | 10.3M |
Additional Tools for Modus Stock Analysis
When running Modus Therapeutics' price analysis, check to measure Modus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Modus Therapeutics is operating at the current time. Most of Modus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Modus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Modus Therapeutics' price. Additionally, you may evaluate how the addition of Modus Therapeutics to your portfolios can decrease your overall portfolio volatility.